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Introduction
Neurofibromatosis type 1 (NF1) is caused by germline mutations in the NF1 gene and is the most common single-gene disorder affecting ~1 in 3,000 live births (1, 2) . Approximately 8-13% of individuals with NF1 will develop malignant tumors, most commonly Malignant Peripheral Nerve Sheath Tumors (MPNSTs) (3) . NF1-related MPNSTs are highly aggressive sarcomas that frequently metastasize and have five-year survival rates ranging from 20-50% (4) (5) (6) (7) (8) . The mainstay of treatment is surgical resection when possible with consideration of chemotherapy and radiation therapy in select cases. Even though chemotherapy may initially stabilize disease, early responses are typically followed by a rapid evolution of chemoresistance and metastasis (9) .
The NF1 gene encodes neurofibromin, a GTPase-activating protein that regulates RAS (including HRAS, NRAS, and KRAS) and loss of NF1 leads to deregulated RAS signaling. The RAS signaling node activates multiple kinase effector cascades, including the RAF-MEK-ERK pathway. NF1-related MPNSTs have been shown to arise from NF1-null myelinating Schwann cells where neurofibromin deficiency results in RAS deregulation (10) (11) (12) (13) (14) (15) . Plexiform neurofibromas are the benign precursor of NF1-related MPNSTs and are formed by a recruited admixture of NF1 haploinsufficient cells (fibroblasts, mast cells, and perineurial cells) following an initial NF1-loss-of-heterozygosity event in a peripheral nerve Schwann cell (16) (17) (18) . A variety of genomic alterations have been observed in the malignant transformation of benign plexiform neurofibromas into MPNSTs including deleterious mutations that impact cell cycle regulation (CDKN2A), apoptosis (TP53), tumor suppression (PTEN, RASSF1A) and chromatin modification (SUZ12/PRC2 gene family) (19) (20) (21) . Genes encoding receptor tyrosine kinase (RTKs) and their putative ligands are also amplified in MPNSTs, including MET, HGF, EGFR, ERBB2, PDGFRα, and c-Kit. NF1-related MPNSTs exhibit significant intertumoral heterogeneity, and it is difficult to determine the relative impact of common MPNST genomic alterations on disease progression and therapeutic response (22) (23) (24) .
The oncogene MET encodes a receptor tyrosine kinase that is involved in the progression and metastasis of most solid human cancers (25) (26) (27) . The pleiotropic effects of MET activation are mediated through a variety of effector pathways including dominant regulators of cellular proliferation and survival (i.e. RAS/ERK, PI3K/AKT/mTOR) and cellular motility (STAT3, Rho kinases. Several studies have implicated oncogenic MET signal activation in NF1-related MPNST disease progression. An increase in MET expression has been observed in the malignant transformation of plexiform neurofibromas into MPNSTs (28) .
Furthermore, high-resolution array-CGH recently identified MET and HGF gene amplifications in a significant proportion (~30%) of NF1-related MPNSTs (24) . MET phosphorylation (Tyr1234/35) was demonstrated in at least half of MPNSTs, and was recently proposed as a biomarker for MET-activated MPNSTs (29) . In this same study, inhibition of MET/VEGFR2/RET (cabozantinib) mitigated tumor growth in an MPNST xenograft model. Currently, it is unclear 1) whether MET activation is sufficient for malignant transformation of NF1-deficient Schwann cells to into MPNSTs, and 2) how the RAS and MET signaling pathways interact in MPNSTs.
Here, we used a longitudinal genomic analysis to identify key genetic events underlying transformation of a plexiform neurofibroma to MPNST. Our results indicate that there is positive selection for MET and HGF copy number gain early in MPNST progression that precedes accumulation of other oncogene amplifications and additional losses of tumor suppression gene function. In order to interrogate the role of MET signaling in MPNST progression and therapy response, we developed and characterized a unique mouse model of MET activation in p53 wild type, NF1-null myelinating cells. Our hypothesis is that MET activation is sufficient to drive malignant tumorigenesis when combined with putative NF1 loss of function, and that MET-activated MPNSTs will respond to targeted MET inhibition. Our findings build upon prior work examining NF1 loss of heterozygosity (LOH) in myelinating cells (30, 31) and present a complementary model of MPNST to established models combining NF1 loss with p53 or Ink4a/Arf (19, 32) . Our results demonstrate that highly selective MET inhibition is effective against MPNSTs bearing a "MET addicted" signature whereby MET inhibition also mitigates downstream RAS-ERK and PI3K-AKT activation. Conversely, we show reduced effectiveness of MET inhibitor monotherapy in Met-amplified NF1-P53 and Hgf-amplified NF1 MPNSTs. These findings are attributable in part to signaling adaptations that occur early during therapy. These results expand our current understanding of the role of MET signaling in MPNST disease progression and identify a potential therapeutic niche for NF1-related MPNSTs. Moreover, these findings highlight the influence of co-occurring genomic alterations on RAS effector signaling and therapy response to tyrosine kinase inhibitors.
Results

Longitudinal genomic analysis of MPNST progression confirms progressive genomic instability
To investigate the genomic alterations that occur during MPNST progression, we followed the disease course of an NF1-affected adolescent male who developed a high grade, metastatic MPNST arising from a chest wall plexiform neurofibroma. Exome sequencing was performed on biopsies procured throughout disease progression: benign plexiform neurofibroma → MPNST pretreatment → MPNST posttreatment → MPNST metastasis ( Figure 1A) . The patient initially presented at 15 years of age with a rapidly enlarging mass in his left axilla that measured 11 x 9 x 17cm by MRI ( Figure 1B To evaluate the genomic alterations that occurred during MPNST progression in this case, tumor DNA was analyzed using a shotgun whole exome sequencing approach. Copy number alterations were inferred using TITAN with the patient's peripheral blood DNA serving as a normal control. The genomic alterations that were identified in each stage of MPNST progression are summarized in a Circos plot ( Figure 1C ). As expected, the plexiform neurofibroma DNA had few copy number variations (ring a, Figure 1C ), but the pre-treatment MPNST demonstrated chromosomal amplifications (orange regions) on chromosomes 1, 7, and 8 (ring b, Figure 1C ). These amplifications were maintained throughout the remaining disease progression. Additional structural alterations and site-specific amplifications accumulated throughout the course of treatment (ring c, Figure 1C ). Regional amplifications on chromosome (chr) 5, chr15, a potential whole chromosomal amplification of chr7, and deletion of chr16 (ring a, Figure 1C) Figure 1D ). The SUZ12 locus was found to be altered in the plexiform neurofibroma, within a genomic segment that while diploid, is representative of a near loss of heterozygosity event on chromosome 17. Somatic mutations in SUZ12 were not observed, but a single germline intron variant was identified. Therefore, the near loss of heterozygosity is representative of a potential genomic structural change within the SUZ12 region of chromosome 17. The observed structural alterations appear to be nonrandom and favor gain of oncogenic receptor tyrosine kinases and loss of TP53.
The earliest observed genomic alterations in the MPNST were balanced copy number gains in MET, HGF, EGFR, and to a lesser degree amplification of CDKN2D. Changes in these specific loci preceded other sites of additional oncogene amplification or tumor suppressor loss.
The number of amplified MET, HGF, and EGFR loci continued to increase during MPNST progression ( Figure 2A) . Specifically, the copy numbers of MET, HGF, and EGFR progressed from a balanced conformation relative to ploidy state in the pre-treatment MPNST, to an imbalanced amplification above regional ploidy state in the recurrent MPNST ( Figure 1D , Figure   2A ). MET copy number gain was confirmed in the pretreatment and recurrent MPNST using quantitative copy number PCR (Supplemental Figure 1) . Loss of NF1 and TP53 was also observed in the pre-, post-and recurrent-MPNST samples ( Figure 1D , Figure 2B ). Interestingly, the non-synonymous coding alteration in the TP53 gene, NC_000017.11:g.7673223G>C, was found to be present in combination with TP53 hemizygosity in all stages of the MPNST. A similar phenomenon was observed for a synonymous coding mutation at the hemizygous CDKN2A locus in the metastatic tumor. Copy neutral loss of heterozygosity events were observed in the posttreatment sample in the genes CHD4, EED, EPC1, PTEN, and RASSF1. These observations demonstrate an important role for MET and HGF in the earliest stages of MPNST disease progression.
Met amplification and NF1 loss in peripheral nerve myelinating cells is sufficient to induce
MPNST formation
To interrogate the role of MET activation in NF1-related MPNSTs, we developed a mouse model that reflects MET amplification in the context of NF1 deficiency. In this Cre-inducible mouse model ( Figure 3A) , a humanized MET transgene that was previously shown to activate MET signaling above physiologic thresholds in neuronal tissue (33, 34) was combined with NF1 deficiency in myelinating Schwann cells (30, 35) . These two genetic events were induced immediately after birth using a tamoxifen-inducible Plp-creERT transgene (36) ;Met;Cre, and wild-type) were aged for up to 600 days to evaluate their tumor phenotypes.
The tumor free survival of NF1-MET mice was significantly decreased relative to the other four mouse lines (all FDR q < 0.001, Figure 3C and Supplemental Table 1 ). Table 2 ).
In total, 70% of NF1-MET mice developed neoplasms, 50% of which were MPNSTs; whereas in the 13% of control mice that developed neoplasms, none were MPNSTs ( Figure 3C ). to the NF1-MET MPNST ( Figure 3E ).
MPNSTs derived from
Copy number gains of MET and HGF observed in murine MPNSTs
Fluorescence in situ hybridization (FISH) was used to evaluate the Rosa26-targeted MET transgene, the endogenous mouse Met gene, and the endogenous mouse Hgf gene. Confirmation of the transgene was performed with a R26-MET probe in NF1-MET mice. In normal spleen from a NF1-MET mouse, we observed 2-4 copies of the MET transgene and in MPNSTs we observed 2-8 MET transgene copies (Supplemental Figure 2 and Supplemental Table 3 ). We also performed FISH analysis to determine whether endogenous Met or Hgf were amplified in the MPNST tumors from the various NF1 mouse lines. We did not observe any additional endogenous mouse Met copy number gains in NF1-MET tumors ( Figure 4A , Supplemental Table 4 ).
Conversely, the NF1-P53 MPNST had a Met copy number gain of 2 in 50% of cells and the NF1
MPNST had a single Hgf copy number gain in 13% of MPNST cells ( Figure 4B -C, Supplemental Table 4 ). To ensure the robustness of these models, each founder and the derived tumors were sequenced to verify both induced and spontaneous mutations. Table 5 ).
These results demonstrate the significant efficacy of MET inhibition in NF1-related MPNSTs with high MET expression and activity. Moreover, the results of capmatinib treatment in the NF1-P53
and NF1 lines suggest that MET inhibition is effective in reducing growth rate in a subset of
tumors, yet combination therapy may be a more effective approach in MPNSTs with these genomic backgrounds.
Discussion
The lack of effective therapies for MPNSTs remains a significant issue for individuals affected by NF1 (5-8). Our purpose in examining the evolution of genomic alterations in the case of a single, NF1-related human MPNST is twofold. Our first objective was to determine the degree of genomic instability that occurs over the course of MPNST treatment following malignant transformation. Intertumoral genomic heterogeneity is well documented in NF1-related MPNSTs (19, 20, 23, 24, 43) , however expression profiling studies do not necessarily support molecular subtyping at the expression level (23) . One theory is that an initial catastrophic event drives To investigate the therapeutic potential of MET inhibition among our series of genomically diverse tumorgraft models, we chose the highly selective MET inhibitor, capmatinib which is currently being tested in the setting of EGFR therapy resistance in NSCLC. We demonstrate that MET-activated (NF1-MET) MPNSTs were uniformly sensitive to capmatinib therapy whereas Metamplified NF1-P53 and Hgf-amplified NF1 tumors were only partially inhibited due to response heterogeneity within individual treatment groups. These data represent the first demonstration of capmatinib treatment response in NF1-related MPNSTs. It follows that when MET activation occurs a priori, the subsequently derived MPNSTs exhibit a MET-addicted signature whereby both RAS-ERK and PI3K-AKT activation are completely suppressed by selective MET inhibition.
These findings further support the concept that MET inhibition is a viable treatment option for the subset of MPNSTs bearing a MET-addicted signature. Currently, it is difficult to define the size or makeup of the "MET-addicted" clinical subset in the NF1 population due to the lack of suitable biomarkers, however MET Y1234/35 phosphorylation has been proposed as a candidate immunohistochemical marker to define MET-activated MPNSTs, and predict MET inhibitor response (29) .
As discussed previously, we observed a heterogeneous treatment response to capmatinib in the NF1-P53 and NF1 tumor groups. One explanation for this partial response is that MPNSTs maintain a fundamental plasticity for reprogramming of RAS effector kinase signaling in the setting of MET inhibition similar to what is observed in breast, lung, and gastric cancers (62) (63) (64) (65) (66) .
The majority of RTKs drive RAS/ERK and PI3K/AKT/mTOR signaling therefore resistance to MET inhibition may be mediated through alternative RTKs that are recruited to support RAS/ERK and PI3K/AKT signaling such as EGFR, PDGFR or both. Alternatively, the emergence of secondary genomic alterations could also drive selection of resistant cell populations. In the NF1-P53 murine MPNST model, EGFR overexpression occurs as a result of locus-specific amplification (58) . 
Statistical Methods
Kaplan-Meier curves were used to display tumor-free survival and, after verifying the proportional hazards assumption, Cox regression with false discovery rate adjusted contrasts were used to test for differences in tumor incidence rates between mouse lines. Three mice euthanized due to hindlimb paralysis had evidence of small paraspinal neoplasms at necropsy and were therefore included as tumor events. Genotypes with no tumor events are not shown. Logistic regression with false discovery rate adjusted contrasts were used to test for differences in the frequencies at which the different mouse lines were euthanized/died early due to tumor burden. Linear mixedeffects models with false discovery rate adjusted contrasts were used to estimate and compare tumor growth rates between different capmatinib dosages within each line. Fiellers's theorem with Bonferroni adjusted significance level was used to estimate the confidence intervals for the percent reduction in tumor growth rates for mice treated with capmatinib versus vehicle across the different lines (68) . All analyses were conducted using R v3.2.2 (https://cran.r-projec t.org/) with an assumed level of significance of α = 0.05.
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